Full Product Name
MYL3 siRNA (Rat)
Product Synonym Names
MLC1V; Myosin light chain 3; Myosin light chain 1. slow-twitch muscle B/ventricular isoform; MLC1SB; Ventricular/slow twitch myosin alkali light chain
Product Gene Name
MYL3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P16409
Specificity
MYL3 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat MYL3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of MYL3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
MYL3 sirna
siRNA to inhibit MYL3 expression using RNA interference
Applications Tested/Suitable for MYL3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for MYL3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_036738.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012606.2
[Other Products]
UniProt Primary Accession #
P16409
[Other Products]
UniProt Related Accession #
P16409[Other Products]
Molecular Weight
22,156 Da
NCBI Official Full Name
myosin light chain 3
NCBI Official Synonym Full Names
myosin, light chain 3, alkali; ventricular, skeletal, slow
NCBI Official Symbol
Myl3 [Similar Products]
NCBI Official Synonym Symbols
Mylc1v
[Similar Products]
NCBI Protein Information
myosin light chain 3
UniProt Protein Name
Myosin light chain 3
UniProt Synonym Protein Names
Myosin light chain 1, slow-twitch muscle B/ventricular isoform; MLC1SB; Ventricular/slow twitch myosin alkali light chain
UniProt Gene Name
Myl3 [Similar Products]
UniProt Synonym Gene Names
Mlc1v; MLC1SB [Similar Products]
UniProt Entry Name
MYL3_RAT
NCBI Summary for MYL3
predominant myosin light chain in cardiac tissue [RGD, Feb 2006]
UniProt Comments for MYL3
MYL3: Regulatory light chain of myosin. Does not bind calcium. Defects in MYL3 are the cause of familial hypertrophic cardiomyopathy type 8 (CMH8). Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. CMH8 inheritance can be autosomal dominant or recessive.
Protein type: Motor; Motility/polarity/chemotaxis
Cellular Component: I band; myosin complex; A band
Molecular Function: actin monomer binding; motor activity; calcium ion binding
Biological Process: skeletal muscle development; muscle contraction; metabolic process; regulation of striated muscle contraction; ventricular cardiac muscle morphogenesis; regulation of the force of heart contraction; cardiac muscle contraction
Research Articles on MYL3
1. Slowing of shortening velocity in type IIb fibers with hindlimb unloading involves a decrease in the relative amount of Myl3.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
